VRAX
Virax Biolabs Group·NASDAQ
--
--(--)
--
--(--)
VRAX fundamentals
During H1 2026, Virax Biolabs Group (VRAX) reported revenue of 1.61K, a YoY change of -67.53%. Net income was -2.34M, a YoY change of 14.99%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2020 | H1,2021 | FY,2021 | H1,2022 | FY,2022 | H1,2023 | FY,2023 | H1,2024 | FY,2024 | H1,2025 | FY,2025 | H1,2026 | TTM |
|---|
Start Date | Apr 1, 2019 | Apr 1, 2020 | Apr 1, 2020 | Apr 1, 2021 | Apr 1, 2021 | Apr 1, 2022 | Apr 1, 2022 | Apr 1, 2023 | Apr 1, 2023 | Apr 1, 2024 | Apr 1, 2024 | Apr 1, 2025 | -- |
End Date | Mar 31, 2020 | Sep 30, 2020 | Mar 31, 2021 | Sep 30, 2021 | Mar 31, 2022 | Sep 30, 2022 | Mar 31, 2023 | Sep 30, 2023 | Mar 31, 2024 | Sep 30, 2024 | Mar 31, 2025 | Sep 30, 2025 | -- |
Fiscal Year-End | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | -- |
Revenue | 99.88K -- | 14.00K -- | 123.82K +23.97% | -- -- | -- -- | 5.76K -- | 8.56K -- | 76.50K +1228.13% | 156.42K +1727.11% | 4.95K -93.53% | 6.33K -95.95% | 1.61K -67.53% | 2.99K -- |
Sales and Services Revenue | 99.88K -- | 14.00K -- | 123.82K +23.97% | -- -- | 0 -100.00% | 5.76K -- | 8.56K -- | 76.50K +1228.13% | 156.42K +1727.11% | 4.95K -93.53% | 6.33K -95.95% | 1.61K -67.53% | 2.99K -- |
Cost of Revenue | 54.13K -- | -- -- | 133.25K +146.19% | -- -- | -- -- | 5.64K -- | 9.93K -- | 65.98K +1069.48% | 105.83K +966.18% | 11.43K -82.68% | 59.40K -43.87% | 321 -97.19% | 48.29K -- |
Cost of Goods and Services | -- -- | -- -- | 133.25K -- | -- -- | 0 -100.00% | -- -- | 9.93K -- | 65.98K -- | 105.83K +966.18% | 11.43K -82.68% | 59.40K -43.87% | 321 -97.19% | 48.29K -- |
Gross Profit | 45.75K -- | 14.00K -- | -9.43K -120.62% | -- -- | 0 +100.00% | 118 -- | -1.36K -- | 10.52K +8813.56% | 50.59K +3806.23% | -6.47K -161.55% | -53.07K -204.90% | 1.29K +119.88% | -45.31K -- |
Operating Expenses | 696.99K -- | 385.46K -- | 635.10K -8.88% | 566.74K +47.03% | 1.73M +172.98% | 1.44M +154.21% | 5.73M +230.59% | 2.72M +88.57% | 6.55M +14.23% | 2.87M +5.73% | 6.11M -6.68% | 2.59M -9.94% | 5.82M -- |
Selling, General and Administrative Expenses | 609.99K -- | 326.96K -- | 514.88K -15.59% | 458.64K +40.28% | 1.30M +152.47% | 1.34M +193.05% | 3.55M +173.25% | 2.11M +56.94% | 4.59M +29.35% | 2.15M +1.74% | 4.33M -5.76% | 1.21M -43.76% | 3.39M -- |
Selling and Marketing Expenses | -- -- | -- -- | 57.20K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
General and Administrative Expenses | -- -- | -- -- | 457.68K -- | -- -- | 1.30M +184.03% | -- -- | 3.55M +173.25% | 2.11M -- | 4.59M +29.35% | 2.15M +1.74% | 4.33M -5.76% | 1.21M -43.76% | 3.39M -- |
Research and Development Expenses | 87.00K -- | 58.50K -- | 120.22K +38.19% | 108.10K +84.78% | 433.74K +260.79% | 96.62K -10.62% | 2.18M +402.45% | 607.34K +528.58% | 1.56M -28.33% | 726.41K +19.60% | 1.78M +13.95% | 1.38M +89.94% | 2.43M -- |
Loss on Impairment of Other Assets | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- | 390.36K -- | -- -- | 0 -100.00% | -- -- | -- -- |
Operating Income | -651.24K -- | -371.46K -- | -644.54K +1.03% | -566.74K -52.57% | -1.73M -168.98% | -1.44M -154.19% | -5.73M -230.67% | -2.71M -87.86% | -6.50M -13.32% | -2.88M -6.38% | -6.16M +5.13% | -2.59M +10.19% | -5.87M -- |
Non-Operating Income (Loss) | -88.22K -- | -18.12K -- | -28.38K +67.83% | -8.30K +54.20% | -16.19K +42.94% | -13.21K -59.16% | 275.00K +1798.46% | -207.98K -1474.42% | -242.65K -188.24% | -14.33K +93.11% | -41.00K +83.10% | -31.39K -119.00% | -58.05K -- |
Other Non-Operating Income (Loss) | 2.47K -- | 7 -- | 266 -89.23% | 5.84K +83385.71% | -753 -383.08% | -3.60K -161.64% | 290.47K +38674.50% | -197.87K -5393.25% | -215.77K -174.28% | 11.26K +105.69% | 17.18K +107.96% | -401 -103.56% | 5.53K -- |
Net Interest Expense | 90.69K -- | 18.13K -- | 28.64K -68.42% | 14.14K -21.98% | 15.44K -46.10% | 9.61K -32.07% | 15.47K +0.19% | 10.11K +5.27% | 26.88K +73.77% | 25.59K +153.03% | 58.18K +116.46% | 30.99K +21.10% | 63.58K -- |
Pretax Income From Continuing Operations | -739.46K -- | -389.58K -- | -672.91K +9.00% | -575.04K -47.60% | -1.75M -160.04% | -1.45M -152.81% | -5.46M -211.90% | -2.91M -100.46% | -6.74M -23.48% | -2.89M +0.72% | -6.20M +7.94% | -2.62M +9.55% | -5.93M -- |
Income Tax Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -136.66K -- | -136.66K -- | -273.59K -100.20% | -273.59K -- |
Net Income | -739.46K -- | -389.58K -- | -672.91K +9.00% | -575.04K -47.60% | -1.75M -160.04% | -1.45M -152.81% | -5.46M -211.90% | -2.91M -100.46% | -6.74M -23.48% | -2.76M +5.41% | -6.07M +9.97% | -2.34M +14.99% | -5.65M -- |
Net Income Attributable to Minority Interests | -29.02K -- | -46.12K -- | -21.93K +24.44% | -22.62K +50.95% | -41.04K -87.15% | -10.18K +55.03% | -269 +99.34% | -4.55K +55.26% | -5.58K -1975.46% | -137 +96.99% | -5.99K -7.20% | -4.50K -3186.13% | -10.35K -- |
Net Income Attributable to Owners of the Company | -710.44K -- | -343.46K -- | -650.98K +8.37% | -552.42K -60.84% | -1.71M -162.50% | -1.44M -161.33% | -5.46M -219.37% | -2.91M -101.55% | -6.73M -23.38% | -2.76M +5.27% | -6.06M +9.98% | -2.34M +15.15% | -5.64M -- |
Net Income Attributable to Common Stockholders | -710.44K -- | -343.46K -- | -650.98K +8.37% | -552.42K -60.84% | -1.71M -162.50% | -1.44M -161.33% | -5.46M -219.37% | -2.91M -101.55% | -6.73M -23.38% | -2.76M +5.27% | -6.06M +9.98% | -2.34M +15.15% | -5.64M -- |
Other Comprehensive Income | 937 -- | -3.27K -- | -3.70K -494.98% | 441 +113.48% | 965 +126.07% | -111 -125.17% | 111 -88.50% | -132.85K -119581.08% | 3.64K +3178.38% | 80.76K +160.79% | 110.38K +2933.22% | -167.58K -307.50% | -137.96K -- |
Total Comprehensive Income | -738.53K -- | -392.85K -- | -676.62K +8.38% | -574.60K -46.26% | -1.75M -158.48% | -1.45M -153.03% | -5.46M -212.06% | -3.05M -109.58% | -6.74M -23.41% | -2.68M +12.18% | -5.96M +11.56% | -2.51M +6.16% | -5.79M -- |
Total Comprehensive Income Attributable to Minority Interests | -32.97K -- | -17.54K -- | -30.20K +8.38% | -25.65K -46.26% | -78.06K -158.48% | -10.18K +60.33% | -269 +99.66% | -4.55K +55.26% | -5.58K -1975.46% | -137 +96.99% | -5.99K -7.20% | -4.50K -3186.13% | -10.35K -- |
Total Comprehensive Income Attributable to Owners of the Company | -705.56K -- | -375.32K -- | -646.41K +8.38% | -548.95K -46.26% | -1.67M -158.48% | -1.44M -163.00% | -5.46M -226.63% | -3.04M -110.74% | -6.73M -23.32% | -2.68M +12.06% | -5.95M +11.58% | -2.51M +6.33% | -5.78M -- |
Basic EPS | -1.14 -- | -0.24 -- | -0.41 +64.04% | -0.24 -- | -1.79 -336.59% | -0.38 -58.33% | -5.13 -186.59% | -1.64 -331.58% | -3.36 +34.50% | -0.89 +45.73% | -1.62 +51.79% | -0.49 +44.94% | -1.22 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -0.41 -- | -- -- | -1.79 -336.59% | -- -- | -5.13 -186.59% | -1.64 -- | -3.36 +34.50% | -0.89 +45.73% | -- -- | -0.49 +44.94% | -- -- |
Diluted EPS | -1.14 -- | -0.24 -- | -0.41 +64.04% | -0.24 -- | -1.79 -336.59% | -0.38 -58.33% | -5.13 -186.59% | -1.64 -331.58% | -3.36 +34.50% | -0.89 +45.73% | -1.62 +51.79% | -0.49 +44.94% | -1.22 -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -0.41 -- | -- -- | -1.79 -336.59% | -- -- | -5.13 -186.59% | -1.64 -- | -3.36 +34.50% | -0.89 +45.73% | -- -- | -0.49 +44.94% | -- -- |
You can ask Aime
What were the key takeaways from Virax Biolabs Group’s earnings call?What were the key takeaways from Virax Biolabs Group's earnings call?What is Virax Biolabs Group's latest dividend and current dividend yield?What guidance did Virax Biolabs Group's management provide for the next earnings period?Did Virax Biolabs Group beat or miss consensus estimates last quarter?What is the market's earnings forecast for Virax Biolabs Group next quarter?What does Virax Biolabs Group do and what are its main business segments?What factors drove the changes in Virax Biolabs Group's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
